Propensity score analysis: Frontline therapy with hyper-CVAD (HCVAD) + ponatinib vs. HCVAD + dasatinib in patients (pts) with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL).
7025 Background: Combination of chemotherapy and tyrosine kinase inhibitor is standard of care in Ph+ ALL. The combination of HCVAD plus ponatinib induced a 3-y survival rate of 80%. The clinical efficacy of this combination has not been compared to that of HCVAD plus dasatinib. Methods: Response and survival for 109 pts with newly diagnosed Ph+ ALL enrolled in two consecutive prospective phase 2 clinical trials of frontline HCVAD with either ponatinib (n = 47; NCT01424982) or dasatinib (n = 62; NCT00390793) were analyzed. Logistic regression after multiple imputations for missing variables was used for propensity score (PS) calculation from baseline pt characteristics. PS analysis with 1:1 matching was performed with the nearest matching method with a caliper of 0.20. Results: PS matching identified 42 pts in each cohort (table 1). The median follow-up for pts treated with HCVAD and ponatinib and HCVAD and dasatinib was 31 and 67 months, respectively. Complete response (CR) rate and minimal residual disease (MRD) status at CR did not differ [CR, 100% vs. 95%, respectively (p = .359); MRD, 74% vs. 56%, respectively (p = .091)]. 1-y and 3-y EFS and OS were superior with HCVAD + ponatinib compared to HCVAD + dasatinib [1-y and 3-y EFS; 86% and 73% vs. 69% and 50%, respectively (p = .035): 1-y and 3-y OS; 89% and 83% vs. 74% and 60%, respectively (p = .041)]. Conclusions: The clinical outcome of HCVAD + ponatinib appears superior to that of HCVAD + dasatinib. Prospective confirmation of these results is warranted.